Landsteiner has restructured its debt and received an equity injection from BID Group
Landsteiner Scientific has completed the successful restructuring of US$190 million of debt under Chapter 11 and has received an equity injection of US$ 20 million from BID Group.
Founded in 1998, Landsteiner is a Mexican pharmaceutical company leader on the development, manufacture and distribution of generic and biotechnological healthcare products. The company operates two state-of-the-art pharmaceutical plants. Landsteiner has over 100 registered molecules from 16 different therapeutic areas and has over 200 different product presentations.
BID Group is an investment fund founded in Mexico City. The group consists of seven business units successfully built over the past 25 years: payroll loan, financial services, IT projects, energy/power supply, construction and operation of infrastructures, venture capital and medical supply solutions.
Oaklins’ team in Mexico acted as the financial advisor to Landsteiner Scientific in the debt restructuring as well as in the structuring of the stock acquisition by BID Group.
Talk to the deal team
Related deals
Dolmans Landscaping Group has welcomed Foreman Capital as a new shareholder to support further growth
Dolmans Landscaping Group, a leading full-service provider of landscaping services, has welcomed Foreman Capital as a new shareholder. By partnering with Foreman Capital, which has extensive experience in building stronger companies in the maintenance of public spaces, Dolmans can accelerate its growth trajectory across core verticals and further professionalize the business.
Learn moreValmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more